{
    "xml": "<topic id=\"PHP2264\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/zuclopenthixol-acetate\" basename=\"zuclopenthixol-acetate\" title=\"ZUCLOPENTHIXOL ACETATE\">\n<title>ZUCLOPENTHIXOL ACETATE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_390\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/thioxanthenes/zuclopenthixol\">Zuclopenthixol</xref>\n</p>\n<data name=\"vtmid\">321584004</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_182743901\" title=\"Antipsychotics (first-generation)\">Antipsychotics (first-generation)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP66014\" outputclass=\"indicationsAndDose\" rev=\"1.15\" parent=\"/drugs/zuclopenthixol-acetate\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Short-term management of acute psychosis</p>\n<p outputclass=\"therapeuticIndication\">Short-term management of mania</p>\n<p outputclass=\"therapeuticIndication\">Short-term management of exacerbation of chronic psychosis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>50&#8211;150&#8239;mg, then 50&#8211;150&#8239;mg after 2&#8211;3&#8239;days, repeated if necessary maximum duration of treatment 2 weeks, to be administered into the gluteal muscle or lateral thigh, 1 additional dose may be needed 1&#8211;2 days after the first injection, maximum cumulative dose 400&#8239;mg in 2 weeks and maximum 4 injections, if maintenance treatment necessary change to an oral antipsychotic 2&#8211;3 days after last injection, or to a longer acting antipsychotic depot injection given concomitantly with last injection of zuclopenthixol acetate.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>50&#8211;100&#8239;mg, then 50&#8211;100&#8239;mg after 2&#8211;3&#8239;days, repeated if necessary maximum duration of treatment 2 weeks, to be administered into the gluteal muscle or lateral thigh, 1 additional dose may be needed 1&#8211;2 days after the first injection, maximum cumulative dose 400&#8239;mg in 2 weeks and maximum 4 injections, if maintenance treatment necessary change to an oral antipsychotic 2&#8211;3 days after last injection, or to a longer acting antipsychotic depot injection given concomitantly with last injection of zuclopenthixol acetate.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66048\" outputclass=\"importantSafetyInformation\" rev=\"1.7\" parent=\"/drugs/zuclopenthixol-acetate\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p>When prescribing, dispensing, or administering, check that this is the correct preparation&#8212;this preparation is usually used in hospital for an <i>acute episode</i> and should <b>not</b> be confused with depot preparations which are usually used in the community or clinics for <i>maintenance</i> treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66052\" outputclass=\"contraindications\" rev=\"1.8\" parent=\"/drugs/zuclopenthixol-acetate\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">CNS depression</ph>; <ph outputclass=\"contraindication\">comatose states</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66061\" outputclass=\"cautions\" rev=\"1.12\" parent=\"/drugs/zuclopenthixol-acetate\">\n<title>Cautions</title>\n<body>\r\n<section outputclass=\"cautions\">\r\n<p>\r\n<ph outputclass=\"caution\">Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP66005\" outputclass=\"pregnancy\" parent=\"/drugs/zuclopenthixol-acetate\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66070\" outputclass=\"breastFeeding\" parent=\"/drugs/zuclopenthixol-acetate\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p>\n<p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p>\n<p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66030\" outputclass=\"hepaticImpairment\" parent=\"/drugs/zuclopenthixol-acetate\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can precipitate coma.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65984\" outputclass=\"renalImpairment\" parent=\"/drugs/zuclopenthixol-acetate\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2264-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/zuclopenthixol-acetate\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74706\" title=\"Solution for injection\" namespace=\"/drugs/zuclopenthixol-acetate/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_390\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/thioxanthenes/zuclopenthixol\" title=\"Zuclopenthixol\" count=\"1\" rel=\"link\">Zuclopenthixol</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74706\" namespace=\"/drugs/zuclopenthixol-acetate/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP2264",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/zuclopenthixol-acetate",
    "basename": "zuclopenthixol-acetate",
    "title": "ZUCLOPENTHIXOL ACETATE",
    "interactants": [
        {
            "id": "bnf_int_390",
            "label": "Zuclopenthixol"
        }
    ],
    "vtmid": "321584004",
    "drugClassification": [
        "Antipsychotics (first-generation)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Short-term management of acute psychosis",
                        "html": "Short-term management of acute psychosis"
                    },
                    {
                        "textContent": "Short-term management of mania",
                        "html": "Short-term management of mania"
                    },
                    {
                        "textContent": "Short-term management of exacerbation of chronic psychosis",
                        "html": "Short-term management of exacerbation of chronic psychosis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "50&#8211;150 mg, then 50&#8211;150 mg after 2&#8211;3 days, repeated if necessary maximum duration of treatment 2 weeks, to be administered into the gluteal muscle or lateral thigh, 1 additional dose may be needed 1&#8211;2 days after the first injection, maximum cumulative dose 400 mg in 2 weeks and maximum 4 injections, if maintenance treatment necessary change to an oral antipsychotic 2&#8211;3 days after last injection, or to a longer acting antipsychotic depot injection given concomitantly with last injection of zuclopenthixol acetate.",
                        "html": "<p>50&#8211;150&#8239;mg, then 50&#8211;150&#8239;mg after 2&#8211;3&#8239;days, repeated if necessary maximum duration of treatment 2 weeks, to be administered into the gluteal muscle or lateral thigh, 1 additional dose may be needed 1&#8211;2 days after the first injection, maximum cumulative dose 400&#8239;mg in 2 weeks and maximum 4 injections, if maintenance treatment necessary change to an oral antipsychotic 2&#8211;3 days after last injection, or to a longer acting antipsychotic depot injection given concomitantly with last injection of zuclopenthixol acetate.</p>"
                    },
                    {
                        "textContent": "50&#8211;100 mg, then 50&#8211;100 mg after 2&#8211;3 days, repeated if necessary maximum duration of treatment 2 weeks, to be administered into the gluteal muscle or lateral thigh, 1 additional dose may be needed 1&#8211;2 days after the first injection, maximum cumulative dose 400 mg in 2 weeks and maximum 4 injections, if maintenance treatment necessary change to an oral antipsychotic 2&#8211;3 days after last injection, or to a longer acting antipsychotic depot injection given concomitantly with last injection of zuclopenthixol acetate.",
                        "html": "<p>50&#8211;100&#8239;mg, then 50&#8211;100&#8239;mg after 2&#8211;3&#8239;days, repeated if necessary maximum duration of treatment 2 weeks, to be administered into the gluteal muscle or lateral thigh, 1 additional dose may be needed 1&#8211;2 days after the first injection, maximum cumulative dose 400&#8239;mg in 2 weeks and maximum 4 injections, if maintenance treatment necessary change to an oral antipsychotic 2&#8211;3 days after last injection, or to a longer acting antipsychotic depot injection given concomitantly with last injection of zuclopenthixol acetate.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "textContent": "When prescribing, dispensing, or administering, check that this is the correct preparation&#8212;this preparation is usually used in hospital for an acute episode and should not be confused with depot preparations which are usually used in the community or clinics for maintenance treatment.",
                "html": "<p>When prescribing, dispensing, or administering, check that this is the correct preparation&#8212;this preparation is usually used in hospital for an <i>acute episode</i> and should <b>not</b> be confused with depot preparations which are usually used in the community or clinics for <i>maintenance</i> treatment.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "CNS depression",
                "html": "CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "comatose states",
                "html": "comatose states"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Avoid in Acute porphyrias",
                "html": "Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.\n\nAnimal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.\n\nChronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.",
                "html": "<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p><p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p><p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can precipitate coma.",
                "html": "<p>Can precipitate coma.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Start with small doses in severe renal impairment because of increased cerebral sensitivity.",
                "html": "<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74706",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_390",
                "label": "Zuclopenthixol",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74706",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}